256 - Reviving the Antimicrobial Pipeline: Costs, Challenges and Opportunities

Saturday, October 14, 2023

1:45 PM – 3:00 PM US ET

Location: 153 ABC

All relevant financial disclosures have been mitigated.

Moderator(s)

Yohei Doi, MD, PHD

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
Pittsburgh, PA, United States
Elizabeth Hirsch, PharmD (she/her/hers)

Associate Professor
University of Minnesota College of Pharmacy
Minneapolis, MN, United States

Faculty(s)

HS

Henry Skinner, MS MS MJurr PhD

Chief Executive Officer
AMR Action Fund
DP

David Paterson

National University of Singapore, Singapore

Slides
Jomana Musmar, MS, PhD (she/her/hers)

Senior Advisor and Executive Director
OIDP/Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB)
Washington , DC, United States

Slides

Disclosure(s):

Yohei Doi, MD, PHD: bioMerieux: Advisor/Consultant (Ongoing); FujiFilm: Advisor/Consultant (Terminated, December 31, 2022); Gilead Biosciences: Advisor/Consultant (Ongoing), Honoraria (Ongoing); GSK: Advisor/Consultant (Ongoing); Meiji Seika Pharma Co., Ltd.: Advisor/Consultant (Ongoing); Moderna: Advisor/Consultant (Ongoing), Honoraria (Ongoing); MSD Sharp & Dohme: Advisor/Consultant (Terminated, December 31, 2022), Honoraria (Terminated, December 31, 2022); Shionogi: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing)

Elizabeth B. Hirsch, PharmD: Melinta Therapuetics: Honoraria (Terminated); Merck and Company, Inc.: Grant/Research Support (Terminated)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify the economic challenges in developing and sustaining new antimicrobial agents;
explain novel clinical trial designs and their implementation to facilitate antimicrobial drug development;
idenitfy strategies to address AMR from public health perspectives

Presentations:

1:45 PM – 2:10 PM US ET

Economic Challenges and Incentives for Novel Antibiotic Development
Speaker: Henry Skinner, MS MS MJurr PhD – AMR Action Fund
2:10 PM – 2:35 PM US ET

Facilitating Adaptive Clinical Trial Design for Anti-Infectives
Speaker: David Paterson – National University of Singapore
2:35 PM – 3:00 PM US ET

Aligning Pandemic Preparedness and Efforts to Combat AMR
Speaker: Jomana Musmar, MS, PhD (she/her/hers) – OIDP/Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB)